<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helwick, Caroline</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hiukka, Anne</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Fenofibrate Treatment and Renal Function in Type 2 Diabetes: FIELD Helsinki Substudy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-11</style></pages><abstract><style  face="normal" font="default" size="100%">Results from a substudy of Fenofibrate Intervention and Event Lowering in Diabetes [FIELD] study, the largest study of fibrates to date, showed no evidence for direct nephroprotection from fenofibrate use [The Field Study Investigators Lancet 2005]. There was, however, an increase in plasma creatinine.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>